Using Multiplex Immunofluorescence to Better Quantify Treatment-Related Changes in sTILs/PD-L1
Previously Aired on April 22nd, 2021
H&E stromal tumor-infiltrating lymphocyte (sTIL) score and programmed death ligand 1 (PD-L1) SP142 immunohistochemistry assay are prognostic and predictive in early-stage breast cancer but are operator-dependent and may have insufficient precision to characterize dynamic changes in sTILs/PD-L1 in the context of clinical research.
In this webinar, the presenters discuss how multiplex immunofluorescence (mIF) combined with statistical modeling can be used to estimate dynamic changes in sTIL score, PD-L1 expression, and other immune variables from a single paraffin-embedded slide, thus enabling comprehensive characterization of activity of novel immunotherapy agents.
In this webinar you’ll learn:
1. How multiplex immunofluorescence and statistical modeling can be used to more precisely estimate dynamic changes in sTIL score and PD-L1 expression
2. About the concordance of these methodologies with current clinical assays but potentially with greater precision
3. How hierarchical linear modeling can mitigate the effects of intratumoral heterogeneity on immune cell count estimations
Who should attend:
• Academic & industry researchers interested in biomarkers
• CRO personnel
David B. Page, MD
(Presenter) Medical Oncologist Providence Cancer Institute, Portland, OR View Biography
Katherine Sanchez, MD
(Presenter) Medical Resident Baylor College of Medicine View Biography